BRIEF-FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment

Reuters
14 May
BRIEF-FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment

May 14 (Reuters) - Regenxbio Inc RGNX.O:

  • FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MUCOPOLYSACCHARIDOSIS II TREATMENT

  • REGENXBIO INC - FDA GRANTS PRIORITY REVIEW WITH PDUFA DATE NOVEMBER 9, 2025

Source text: ID:nPn8LTm8Ta

Further company coverage: RGNX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10